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Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis (M.tb), remains the leading cause of mortality from a single
infectious agent. Each year around 9 million individuals newly develop active TB disease, and over 2 billion individuals are
latently infected with M.tb worldwide, thus being at risk of developing TB reactivation disease later in life. The underlying
mechanisms and pathways of protection against TB in humans, as well as the dynamics of the host response to M.tb
infection, are incompletely understood. We carried out whole-genome expression profiling on a cohort of TB patients
longitudinally sampled along 3 time-points: during active infection, during treatment, and after completion of curative
treatment. We identified molecular signatures involving the upregulation of type-1 interferon (a/b) mediated signaling and
chronic inflammation during active TB disease in an Indonesian population, in line with results from two recent studies in
ethnically and epidemiologically different populations in Europe and South Africa. Expression profiles were captured in
neutrophil-depleted blood samples, indicating a major contribution of lymphocytes and myeloid cells. Expression of type-1
interferon (a/b) genes mediated was also upregulated in the lungs of M.tb infected mice and in infected human
macrophages. In patients, the regulated gene expression-signature normalized during treatment, including the type-1
interferon mediated signaling and a concurrent opposite regulation of interferon-gamma. Further analysis revealed IL15RA,
UBE2L6 and GBP4 as molecules involved in the type-I interferon response in all three experimental models. Our data is highly
suggestive that the innate immune type-I interferon signaling cascade could be used as a quantitative tool for monitoring
active TB disease, and provide evidence that components of the patient’s blood gene expression signature bear similarities
to the pulmonary and macrophage response to mycobacterial infection.
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Introduction
Approximately one third of the world’s population is estimated
to be latently infected with Mycobacterium tuberculosis (M.tb), the
etiological agent of tuberculosis (TB), which is responsible for
about 8–10 million active new cases of TB each year [1,2]. A
bacteriologically confirmed diagnosis of TB is challenging, as
direct microscopy has low sensitivity, bacterial culture takes 2 to 4
weeks, and sputum samples can be microbiologically false
negative. Effective treatment of active TB is crucial in containing
spread of the disease, and better diagnostics would greatly impact
on TB control by facilitating early treatment. Little is known about
the precise mechanisms and pathways that control protective
versus pathogenic immunity during TB [3,4]. The IL-12/IFN-c
and the TNF/TNFR axis are both crucial in protection during
M.tb infection, as genetic (e.g. defects in the IL-12/IL-23/IFN-c/
STAT1 axis) or acquired (HIV; immune-suppressants; anti-
cytokine auto-antibodies) defects strongly increase host-suscepti-
bility to mycobacterial disease [5–7]. IFN-c is produced mostly by
CD4+ T cells and assists macrophages in controlling intracellular
M.tb infection through various anti-microbial immunity pathways,
which include phagosomal maturation; anti-microbial peptides;
oxidative stress; apoptosis and autophagy [8]. Although IFN-c is
essential to protection against M.tb, it is not in itself a correlate of
protection, however.
Several studies have profiled gene expression patterns in
peripheral blood fromTB patients [9–15]. In amost comprehensive
recent study, Berry et al. [15] reported a previously unappreciated
role of IFN-ab signaling in TB pathogenesis. Blood transcriptional
profiles of active TB patients were dominated by a neutrophil driven
IFN-ab inducible gene expression profile [15]. A more recent study
compared gene expression patterns in the blood of tuberculosis and
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sarcoidosis patients (of European descent), a chronic inflammatory
lung disease with granulomatous inflammatory pathology similar to
TB, and observed a very similar pattern in gene-expression, miRNA
expression and serum cytokine levels between the two diseases [16].
These data strongly suggest the presence of a major core pro-
inflammatory pathway in TB and sarcoidosis, although also disease
specific patterns could be distinguishedmarking TB and sarcoidosis.
Thus there has been substantial success in identifying biomarkers
associated with active TB.
Notwithstanding the value of these two genome wide gene
expression studies reported recently, a major outstanding question
is whether these signatures, captured mostly in EU and South
African populations, also translate to populations and regions with
a very different host genetic and TB epidemiological background.
Our study addresses this issue directly by assessing unbiased whole
genome expression profiles in Indonesia, an Asian country with
the third highest TB prevalence worldwide. Specifically, we have
examined gene expression patterns in PBMC from a longitudinal
patient cohort during active TB, TB treatment and TB
convalescence. Moreover, we replicated the findings in two
independent model systems, a mouse M.tb-infection model and a
mycobacterium-infected human macrophage cell line model.
Although mouse models typically do not develop caseous necrotic
lesions, the hallmark of human pulmonary TB [17], both mice and
humans develop TB granulomas in the lung with activation of
similar pro-inflammatory and anti-inflammatory responses [18],
and develop highly parallel innate and adaptive immune responses
during M.tb infection [8,19,20]. Our results validate and
significantly extend the results available in the current literature,
extend these to different ethnic and TB epidemiological settings,
and further refine the pro-inflammatory biomarker signature
associated with active TB.
Results
Gene Expression Profiles of Active TB Patients Versus
Healthy Controls in a Longitudinal Patient Cohort from
Indonesia
To identify molecular signatures involved in active TB, we
applied microarray analysis to compare global gene expression in
23 patients with active TB (t = 0 weeks), whilst they were
undergoing treatment (t = 8 weeks), and after they had completed
the entire course of treatment (t = 28 weeks). The same microarray
analysis was also applied to 23 matched healthy controls from the
same population from the same area (see Methods). A total of 875
transcripts were significantly differentially expressed with an
additional filter of a fold change greater than 2 compared to
controls. The heatmap generated by these transcripts is shown
(Figure 1). Looking at the overall gene-expression profile patterns
as a continuum from active disease (t = 0 weeks) to treatment (t = 8
weeks) and cure (t = 28 weeks), we observed that global gene
expression profile patterns were more similar for patients in the
active disease stage (t = 0 weeks) and at the treatment stage (t = 8
weeks), whilst the gene expression profile patterns for patients after
28 weeks of curative treatment were more similar to those of the
healthy controls.
Active TB Disease Involves the Expression of Genes
Related to Several Branches of Immunity
Gene ontology clustering was performed on the 875 differentially
expressed transcripts described above using the Panther analysis
software, comparing them to the entire reference list (N$24,000) of
genes. Of the 875 transcripts 460 fall within eight broad groupings
which were most statistically significant: amongst others immunity
and defense, interferon-mediated and macrophage-mediated im-
munity, and the chemokine and cytokine pathways (Table 1,
Bonferroni-corrected P-values,0.05 for all the groups).
Differential Gene Regulation in Humans During Active TB
Disease and Upon Treatment
Further analysis was undertaken by hierarchically clustering the
875-transcript list using the Self Organizing Map (SOM)
algorithm in Genespring GX10, taking into account the patients’
disease stage at the time of sampling (untreated active disease
(t = 0), undergoing treatment (t = 8 weeks), during convalescence
after curative treatment (t = 28 weeks)) and for comparison,
healthy controls. In order to distinguish between different
expression profiles across these four conditions, ANOVA was
used and the 875 statistically significant transcripts discovered
from gene ontology clustering were initially subjected to a 3 row by
4 column SOM matrix (model free). Transcripts which exhibited
the same behavior were clustered together, and two groups of
transcripts (Figure 2) can be observed to have the clearest
evidence of increased (Figure 2, left panel) or decreased
expression (Figure 2, right panel) when comparing with active
TB (t = 0 weeks), with time points during treatment (t = 8, 28
weeks), as well as comparing with controls. Both clusters were
investigated for gene ontology clustering using Panther analysis.
Analysis with the group of transcripts showing significantly
increased expression revealed 56 genes which were significantly
involved in discrete biological pathways. The type 1 interferon
mediated immunity (a subgroup of immunity and defense),
underlined by interferon a/b-mediated signaling, was highlighted
as a very significant biological sub-process, (P=5.2161028;
Table 2). Conversely, analysis with the group of transcripts
showing significantly decreased expression revealed 88 genes
involved in significant biological pathways. Apart from immunity
and defense (P=5.84610211), other highly significant biological
processes highlighted include chemokine and chemokine-mediated
signaling (P=4.5361025 Table 3). Interestingly, a concurrent
down-regulation of interferon-gamma was observed.
Comparison of Gene Expression Signatures from the
Longitudinal TB Cohort Versus Those Obtained in a
Human in vitro Macrophage Infection Model
In order to examine whether the findings using patient blood
mRNA responses could be confirmed in a well defined in vitro
human macrophage (THP-1) cell line infection model, THP-1 cells
were infected with the TB vaccine strain, M.bovis BCG (for 20
hours). A total of 461 transcripts were found by microarray
analysis to be significantly differentially expressed in THP-1
macrophages following infection with BCG compared to unin-
fected control cells. A significant proportion, 95 out of these 461
transcripts, was found to be shared with the significantly
differentially in vivo expressed transcripts in the above patient
cohort (Figure 3). These 95 transcripts were investigated for
functional clustering using Panther analysis, of which 77 out of the
95 were found to be significantly involved within functional
clusters. The most significant biological process was again found to
be in interferon mediated immunity (P=1.14610217; Table 4).
Human Host Responses to M.tb Infection Common with
an in vivo Mouse Infection Model
In a third independent approach, we used an in vivo mouse TB
infection model to examine whether the findings in the longitu-
dinal patient cohorts blood samples could be confirmed in the
infected mouse lung, the major organ affected by TB. A total of
Genome-Wide Expression Profiles in Tuberculosis
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1,674 transcripts were found by microarray analysis to be
significantly differentially expressed in C57BL/6 mice infected
with M.tb compared to non-infected controls. Of these transcripts,
121 were common to the significantly differentially expressed
transcripts in the human cohort (Figure 4). These common
transcripts were subjected to Panther gene ontology analysis, and
85 out of the 121 transcripts clustered into significant biological
pathways. The most significant biological pathway was once again
type1 interferon-mediated immunity (Table 5).
Genes Found in Common in All 3 Models of TB
A total of 26 genes (or 33 entities due to the presence of multiple
transcripts for several genes) were found to be significantly
differentially expressed in all 3 models (longitudinal human TB
cohort, human macrophage cell line, and in vivo mouse model;
Table 6, Figure 5). These 26 genes were then subjected to
Ingenuity Pathway Analysis (IPA). The most significant network
(P,10232) includes 18 focus molecules showing a high level of
interaction between these molecules which involves both NFkB
activation and the type I interferon response.
We then proceeded to validate the microarray findings for these
26 genes using quantitative RT-PCR (qRT-PCR); for successful
validation, the direction for the fold-change in gene expression
using qRT-PCR should be consistent with the micro-array
findings. A total of 17 out of the 26 genes were successfully
validated via qRT-PCR in the longitudinal patient cohort and 15
out of the 17 genes were validated in the human macrophage
model (BCG-infected THP-1 cells) (Table 6). These 15 genes
Figure 1. Differential gene expression in blood from TB patients and controls determined by microarrays. Heat map of 875 transcripts
which were statistically different in one condition from the other condition, using ANOVA and were hierarchically clustered. active = patients with
active disease, treatment =patients after 8 weeks of treatment, recovered=patients after 28 weeks of treatment and controls = healthy controls. Red
represents an increase in gene expression and green represents a decrease in gene expression.
doi:10.1371/journal.pone.0045839.g001
Table 1. The distinct pathways in which gene ontology clusters 460 of the 875 differentially expressed genes.
Biological process
Total number
of genes
Number of genes differentially expressed
between active TB patients and controls
Expected number
of genes
Bonferroni corrected
p-value
Immunity and defense 1393 126 53.85 3.57610217
Interferon mediated immunity 69 17 2.67 5.1561027
Macrophage-mediated immunity 150 24 5.8 1.5761026
Cytokine/chemokine mediated signaling
pathway
272 31 10.51 3.5361025
Natural Killer Cell mediated immunity 77 14 2.98 4.2161024
Apoptosis 606 44 23.42 2.261023
T-cell mediated immunity 210 21 8.12 1.561022
Signal transduction 3791 183 146.54 2.161022
Significant pathways and biological processes overrepresented in differentially expressed genes between actively diagnosed patients and healthy controls from Panther
analysis. 460 out of the 875 transcripts identified clustered into significant biological pathways and processes. A Bonferroni-corrected P,0.05 was considered
statistically significant.
doi:10.1371/journal.pone.0045839.t001
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were common to both the human models (longitudinal patient
cohort and BCG-infected THP-1 cells). However, only 5 out of the
17 genes could be validated in the in vivo mouse model (Table 6).
Considering all validation data, 3 genes (IL15RA, UBE2L6 and
GBP4) out of the 26 genes common to all 3 models were found to
be consistently and reproducibly upregulated across 3 model
systems (Figure 6). It is clear from the network analysis (Figure 7)
that IL15RA, UBE2L6 and GBP4 are involved in the type-I
interferon signaling response.
Discussion
Comparing gene expression profiles in 3 models of TB, a
longitudinal human TB cohort study comprising of newly-
diagnosed TB patients followed up through treatment, a BCG-
infected human macrophage cell line and an in vivo mouse lung TB
infection model, we identified in all three models a highly
prominent type-I interferon molecular signature. This result
significantly extends those of Berry et al [15], and Maertzdorf et
al [16]. who found highly similar signatures in the blood of TB
patients in Europe and South Africa; our results now confirm and
extend this to a TB endemic setting on a third continent in a
different host genetic as well as TB epidemiological setting, namely
Indonesia. In addition, our results confirm and validate part of the
findings in two independent models of TB infection, thus
connecting the TB patient blood expression profiles to pulmonary
and macrophage expression signatures.
Our un-biased whole genome microarray analysis revealed that
the most prominent host responses in all three models of infection
were immune related. The most significant pathways were
interferon mediated immunity, macrophage mediated immunity
and cytokine and chemokine mediated signaling pathways.
Further analysis of the differentially expressed genes in the TB
patient study revealed that the type-1 interferon signaling activity
was the predominant pathway up-regulated during active disease,
and that there was concurrent down-regulation of interferon-
gamma. This is consistent with findings that key protective
immune mechanisms are repressed by type-1 interferon signaling
during active TB infection [21,22] as a possible immune evasion
response.
The network analysis of genes found to be commonly regulated
in all 3 independent TB disease models showed that the most
significant network was mainly involved in IL-12, IFN-a and IFN-
b signaling. This is indeed noteworthy as evidence implicating the
involvement of type 1 interferon (IFN-a and IFN-b) in TB have
only begun to emerge very recently [15]. In the present study, we
have shown an up regulation in type 1 interferon (a/b) and the
genes involved. Kuchtey et al., showed that during early infection
(2–3 weeks post infection) there was an enhanced growth of M.
bovis BCG in the lungs of mice deficient in IFN-ab receptors, and
during late infection the burden of BCG was similar in lungs of
IFN-ab2/2 and wild type mice [23]. Desvignes et al. recently
reported a similar non redundant protective role for type-1
interferons during early M.tb infection in a mouse model [24]. In a
large human study using whole blood from active TB patients vs.
uninfected controls, Berry et al., found an increase in type 1 IFN
which was attributed predominantly to neutrophils [15]. Here,
however, we present highly similar findings in TB patients’ blood
leucocytes, which were depleted of neutrophils through Ficoll
density centrifugation, but still include monocyte/macrophages.
The fact that the latter are the most likely source of this signature
was supported by the finding of a similar signature in an
Figure 2. Cluster analysis using self-organizing map with further Panther analysis. Genespring GX10 was used to analyse transcripts which
were significantly different between the four conditions (Active disease, Treatment, Recovered and Controls) using one-way ANOVA and
subsequently subjected to self-organizing map clustering analysis. Upregulated transcripts (left panel) and downregulated transcripts (right panel)
were subjected to further analysis through Panther.
doi:10.1371/journal.pone.0045839.g002
Table 2. The distinct pathways in which gene ontology clusters 56 of the genes with increased expression normalizing during
treatment.
Biological process
Total number
of genes
Number of genes with significantly
increased expression in active TB patients
versus controls, normalizing during
TB treatment
Expected number
of genes
Bonferroni corrected
p-value
Immunity and defense 1393 39 11.20 1.83610210
Type-I interferon mediated immunity 69 10 0.55 5.2161028
Macrophage mediated immunity 150 7 1.21 0.034
Significant Panther biological processes was detected for 56 up-regulated genes, type 1 interferon expression is increased in this group.
doi:10.1371/journal.pone.0045839.t002
Genome-Wide Expression Profiles in Tuberculosis
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independent, human macrophage cell line model of mycobacterial
infection. Also in another study using whole blood to compare
gene expression profiles in TB patients with active disease vs.
individuals with latent M.tb infection several interferon inducible
genes were found to be profoundly upregulated, including IFN-a
protein 6 and 27 and ISG15 [12]. Furthermore, exogenously
added IFN-a was found to inhibit the priming effect of IFN-c on
key cytokine release by monocytes [22]. IFN-b was found to have
a similar effect [25]. This is compatible with a model in which
enhanced type I interferon signaling inhibits type II interferon
mediated protective immunity in TB.
It is unsurprising that of all immune cells and corresponding
signaling systems (T-cells, B-cells, monocytes/dendritic cells/
macrophages, natural killer cells), the macrophage-mediated
immunity process was consistently found to play a dominant role
(Tables 1–4) in the transcriptional response in each of the three
different study models. This highlights the key role that M.tb/
macrophage interactions play during infection. Alveolar macro-
phages phagocytose inhaled M.tb by a wide range of receptors such
as complement receptors CR1, 3 and 4; mannose receptors; Toll-
like receptors; C-type-2 lectin receptors and scavenger receptors
[26]. The further influx of macrophages following the formation of
a primary lesion further highlights the key role of these
professional phagocytes in pulmonary host defence in TB [12].
M.tb however inhibits macrophage activity by inhibiting autoph-
agy, an important cellular mechanism to control intracellular M.tb
[27,28]. In addition, M.tb blocks the maturation of phagosomes
such that they fail to traffic further along the endosomal-lysosomal
pathway and fail to fuse with lysosomes. One newly identified
receptor which may be important in this process is human TLR8.
A polymorphism resulting in a missense mutation in TLR8
(Met1Val) was recently shown to be strongly associated with
human susceptibility to TB [29]. Increased credence to the
possible involvement of TLR8 in upstream M.tb recognition is lent
by findings from the expression array in the longitudinal patient
cohort, which highlighted the significance of the immunity and
defense pathway in active disease, including TLRs. It may be of
interest to note that TLR8 is absent from mice, which could
account for part of the differences in TB infection biology between
humans and mice.
Table 3. The distinct pathways in which gene ontology clusters 88 of the genes with decreased expression normalizing during
treatment.
Biological process
Total number
of genes
Number of genes with significantly
decreased expression in active TB
patients versus controls normalizing
during TB treatment
Expected number
of genes
Bonferroni corrected
p-value
Immunity and defense 1393 35 8.93 5.84610211
Cytokine and chemokine mediated
signaling pathway
272 12 1.74 4.5361025
Ligand mediated signaling 451 14 2.89 2.8361024
Cytokine/chemokine mediated immunity 123 7 0.79 2.4261023
Apoptosis 606 13 3.88 4.7661023
Macrophage mediated immunity 150 7 0.96 8.4261023
Significant Panther biological processes were detected with 88 down-regulated genes; type 2 interferon expression is decreased in this group.
doi:10.1371/journal.pone.0045839.t003
Figure 3. Comparison of differential gene expression between M.tb infected patients and BCG infected THP-1 cells. Venn diagram
representing the 875 significantly differentially expressed in TB patients and 461 transcripts significantly differentially expressed in THP-1 BCG in vitro
model. A total of 95 transcripts were found to be in common between these two systems. Red – transcripts for active TB patients only; Green –
Common between TB patients and BCG-infected THP-1 cell line; Blue – transcripts for BCG-infected THP-1 only.
doi:10.1371/journal.pone.0045839.g003
Genome-Wide Expression Profiles in Tuberculosis
PLOS ONE | www.plosone.org 5 September 2012 | Volume 7 | Issue 9 | e45839
Further validation of our findings using qRT-PCR revealed that
IL15RA, UBE2L6 and GBP4 were involved in this molecular
signature in all three models (Figure 6). IL15RA encodes for
interleukin-15 (IL-15) receptor alpha (IL-15Ra), a common
cytokine receptor expressed by macrophages that plays an
important role in the development, survival, and proliferation of
various immune cells (e.g. natural killer and CD8+ T cells). IL-15,
which is co expressed with IL-15Ra by antigen presenting cells
allowing trans-production of cytokines to immune effector cells
[30] is generally considered to be a regulator of T cell homeostasis
as it cooperates with other cytokines like IL-2 and IL-7 to maintain
pools of naive and memory T cell populations. Mortier et al., has
described that IL-15Ra expression on macrophages supports the
early transition of antigen specific effector CD8+ T cells to
memory cells [31]. As these processes are critical in the early
immune response against microbial infections, and as data on the
potential protective effects of IL-15 on murine experimental
tuberculosis is starting to emerge, further studies are necessary in
order to document the precise mechanism of action of IL-15-
mediated type-I interferon signaling on M.tb survival and
proliferation.
The second gene with consistent validation across the three TB
models studied here, UBE2L6, is a member of the ubiquitin family
of proteins. The modification of proteins with ubiquitin is an
important cellular mechanism for targeting abnormal or short-
lived proteins for degradation, and recent work linking the
ubiquitin family of proteins to type-I interferon mediated host
immune responses is now beginning to emerge [32–35].
The third gene, GBP4, encodes Guanylate binding protein 4.
With IFN-a being a main hypothesis in our study, it is reassuring
that GBP4 was commonly found in all 3 models, and indeed GBP4
displays a direct interaction with IFN-a (Figure 7). Type 1 and 2
IFNs have been shown to differentially regulate the GBP family of
genes, and GBP4 is exclusively regulated by IFN-a production
through macrophages [36].
In our study a substantial number of overlapping genes were
identified when comparing BCG infected human macrophage
cells and circulating leucocytes from TB patients with active
disease (Figure 3). The majority of these genes was present in the
Table 4. Differentially expressed genes in common between active TB patients versus controls and BCG-infected versus
uninfected THP-1 cells.
Biological process
Total number
of genes
Number of genes in common between
active TB patients vs controls and
BCG-infected vs uninfected THP-1 cells
Expected number
of genes
Bonferroni corrected
p-value
Interferon-mediated immunity 69 14 0.29 1.14610217
Immunity and defense 1393 31 5.8 9.22610214
Cytokine/chemokine mediated signaling
pathway
272 10 1.13 4.4361025
Cytokine/chemokine mediated immunity 123 7 0.51 1.3761024
Macrophage mediated immunity 150 6 0.62 6.0861023
Ligand-mediated signaling 451 9 1.88 2.2661022
Significant Panther biological processes were detected from 77 out of the 95 over-represented genes common between the two models.
doi:10.1371/journal.pone.0045839.t004
Figure 4. Comparison of differential gene expression between patients with active TB and mice infected M.tb in vivo model. Venn
diagram representing the 875 significantly differentially expressed in TB patients and 1674 transcripts significantly differentially expressed in TB
actively infected mice. A total of 121 transcripts were found to be in common between these two systems. Red – transcripts for TB patient only; Green
– Common between TB patients and mice infected with TB; Blue – transcripts for mice infected with TB only.
doi:10.1371/journal.pone.0045839.g004
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immune-mediated and host defense pathways. It needs to be
highlighted that these genes were also common when the mouse
TB infection model was compared to the data from the human
models (Figure 4). The genes overlapping in all three systems
were further validated with qRT-PCR. The 15 genes that were
successfully validated in the THP-1 cell line model by qRT-PCR
completely overlapped with the 17 genes validated by qRT-PCR
in the longitudinal patient cohort. (Figure 6). This is not
surprising since both models share a common human host
background. The fact that only 3 genes were common to all
three models may reflect important differences between the
human and mouse models of TB. The PCR validation of these
genes may represent an underestimate of the of the true array
findings as the detection probes did not directly overlap with the
array probes and so may not be able to confirm the specific RNA
transcript identified by the array, particularly in the mouse to
human comparisons. Although the use of BCG rather than M.tb in
the THP-1 infection model may also have contributed to this
relatively low number, it should be emphasized that the analysis
focused only on those genes found in all three models, and that the
variation between the M.tb infected human patients and the M.tb
infected mice was significantly larger that that between the M.tb
infected human patients and the BCG infected THP-1 cells. Our
approach thus excludes the identification of genes based on only
one individual model, and identifies genes only when they have
been validated in three models, which is a significant advance
compared to previous studies. In our study the mice were infected
with M.tb intravenously, and it will be of interest to see whether
infection via the aerosolic route, which is reflective of natural TB
transmission, would have yielded similar response patterns. A
cardinal feature of human TB is of central caseous necrosis in
pulmonary granulomatous lesions, while such necrotic lesions are
not seen in the mouse TB infected lung. Caseous necrosis is
considered an essential step towards developing cavernous TB, in
which phase M.tb bacilli are released into the open airways prior to
transmission. Thus, there are clear differences in the pathological
Table 5. Differentially expressed genes in common between active TB patients versus controls and TB-infected versus uninfected
mice.
Biological process
Total number
of genes
Number of genes in common between
active TB patients vs controls and
TB-infected vs uninfected mice
Expected number
of genes
Bonferroni corrected
p-value
Immunity and defense 1393 39 7.46 6.71610217
Interferon-mediated immunity 69 12 0.37 7.90610213
Macrophage mediated immunity 150 11 0.8 1.0261027
Cytokine/chemokine mediated signaling
pathway
272 11 1.46 5.6361025
Cytokine/chemokine mediated immunity 123 7 0.66 7.4861024
Natural Killer cell mediated immunity 77 5 0.41 9.5161023
Significant Panther biological processes were detected from 85 out of the 121 over-represented genes common between the two models.
doi:10.1371/journal.pone.0045839.t005
Figure 5. Comparison of differential gene expression from all three models. Venn diagram representing the 875 significantly differentially
expressed in TB patients, 461 significantly differentially expressed in BCG-infected THP-1 cells and 1674 transcripts significantly differentially
expressed in TB actively infected mice. A total of 33 transcripts (representing 26 genes) were found to be in common between all three systems. Red
– transcripts for patients with active TB; Blue – transcripts for BCG-infected THP-1 cells; yYellow – transcripts for mice infected with active TB.
doi:10.1371/journal.pone.0045839.g005
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manifestations of TB in human and mouse systems and this
difference in disease pathology has been central to the argument
that the mouse is an imperfect model for TB. However,
notwithstanding these differences, we were able to observe
consistent molecular signatures of active TB across the distinct
models, thus supporting the general conclusion that mouse models
are appropriate for studying certain aspects of the immune
molecular host response to infection.
The use of TB patients cohorts, in vitro human macrophage cell
lines and inbred mouse models of TB have provided new
information which is in line with, but also significantly extends
recent work from other groups [15,16]. Collectively, these studies
demonstrate the major role of dysregulated inflammation in
general, and of strongly enhanced type 1 IFN-ab signaling in
active TB disease. Importantly whereas this latter finding was
originally attributed to the activity of neutrophils, we here find
these same gene expression patterns also in cells devoid of
neutrophils, such as PBMCs and macrophages. Finally, our study
discovered genes commonly expressed in all three TB models we
have studied, for example IL15RA, UBE2L6 and GBP4 which are
all common to the IFN-a network. Future studies should extend
this also to protein expression profiles to determine whether these
differences are also present at the protein level. This will allow
further insights into their possible function during TB disease and
M.tb infection, and help to better delineate new TB biomarker
signatures.
Materials and Methods
Ethical Statement
This study was approved by the Ethical Committee of the
Faculty of Medicine, University of Indonesia, Jakarta, and by the
Eijkman Institute Research Ethics Committee, Jakarta, and
written consent was voluntarily signed by all patients and control
subjects [37].
Patient Recruitment
After informed consent, 23 new pulmonary tuberculosis patients
above 15 years of age were recruited from an outpatient
tuberculosis clinic in central Jakarta (Indonesia) [37]. Diagnosis
of TB was performed according to the World Health Organization
criteria, on the basis of the clinical presentation and a chest X-ray
radiograph (CXR) and confirmed by sputum microscopy positive
for mycobacteria using Ziehl-Nielsen stain. Free anti-TB drug
Table 6. Validation by qRT-PCR of 26 genes differentially expressed in all three models based on microarray analyses.
gene
Validated in longitudinal
cohort TB patients
Validated in BCG-infected
human macrophages
Validated in M.tb-infected
lungs of mice
Direction of expression
changea
BATF2 yes yes no up
C1QC yes no yes up
CCL2 no no no down
CCL7 no no no down
CD40 yes yes no up
CX3CR1 yes no yes up
CXCL10 no no no up
DDX58 yes yes no up
GBP4 yes yes yes up
IFIT2 no no no up
IFIT3 no no no up
IL15RA yes yes yes up
IL1A no no no Down
IMPA2 yes yes no Up
MEFV yes yes no Up
OAS1 yes yes no Up
OAS2 yes yes no Up
PBEF1 no no no Down
PIM1 yes yes no Up
SLAMF7 no no no Up
TLR5 yes yes no Up
TNFAIP2 yes yes no Up
TRAFD1 yes yes no Up
TRIM5 yes yes no Up
UBE2L6 yes yes yes Up
WARS no no no Up
17 genes 15 genes 5 genes
For successful validation, the direction for the fold-change in gene expression using qRT-PCR should be consistent with the microarray findings.
ain longitudinal cohort of TB patients.
doi:10.1371/journal.pone.0045839.t006
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treatment was provided to all patients and consisted of a standard
regimen of isoniazid, rifampin, pyrazinamide and ethambutol
(2HRZE, 4H3R3) for a total of 6 months according to the national
TB program. Treatment was supervised once weekly by a directly
observed treatment program.
Human immunodeficiency virus (HIV)-seropositive patients,
diabetes mellitus affected patients, patients with heart diseases and
patients with incomplete data records were excluded. 23 randomly
selected control subjects with the same sex and age (+/210%)
were recruited from neighboring households, with first degree
relatives excluded. Controls with signs, symptoms and CXR
results suggestive of active TB, a history of prior anti-TB
treatment, diabetes mellitus or incomplete data entry were
excluded. HIV status was not tested in control group. Indonesia
is classified as a country with a low HIV prevalence of #0.1%
during the sample period [38]. Patients’ self reported ethnicities
were recorded upon recruitment. A Javanese origin characterized
three groups – the Jawa, Betawi and Sunda – and altogether
comprised more than 80% of the total sample. The non-Javanese
category included individuals born on other Indonesian islands.
RNA Extraction
Blood samples at three time points of disease spectrum (active
phase: 0 weeks, treatment phase: 8 weeks and convalescent phase:
28 weeks) were obtained and collected in heparinized tubes.
Peripheral blood mononuclear cells (PBMCs) were separated using
a Ficoll density gradient, and kept frozen until use. Total RNA was
extracted using the RNeasy Mini Kit (Qiagen, Germany)
according to the manufacturer’s instructions, and subsequently
subjected to DNAse treatment using RNAse free DNAse Set
(Qiagen, Germany). RNA integrity was assessed by 1% agarose gel
Figure 6. Validating microarray data by qRT-PCR. Microarray results were validated by qRT-PCR. 17 genes from the 26 genes were found to be
significantly different between TB patients with active disease and healthy controls, 15 genes from the 26 genes were found to be significantly
different between live BCG-infected THP-1 cells at 20 hours compared to uninfected controls, and 5 genes from 26 genes were found to be
significantly different between mice infected with active TB and mock infected mice, using student’s T test (P,0.05). Three genes which were
common to all 3 models show similar levels of expression with both techniques applied. The fold increase for microarray technique (blue, orange and
yellow) and qRT-PCR technique (light blue, light orange and light yellow) for patients, THP-1 cells and mice respectively. Microarray data (and their
corresponding qRT-PCR data) that were not validated by qRT-PCR are not shown.
doi:10.1371/journal.pone.0045839.g006
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electrophoresis and samples of poor quality were excluded from
analysis.
Mycobacterium bovis Bacillus Calmette Gue´rin (BCG)
Infection of Differentiated THP-1 Macrophages
The human monocytic cell line THP-1 (ATCC, Rockville, MD)
cells were cultured in RPMI 1640 supplemented with 10% FBS,
penicillin (100 U/ml) and streptomycin (100 mg/ml) (Invitrogen).
Cells were plated at a density of 106 in 6-well tissue culture plates
(Nunclon). Monocytes were allowed to adhere and differentiate
into macrophages for 48 hours with 5 nM PMA (Sigma Aldrich) at
37uC in a humidified atmosphere of 5% CO2. Differentiated
macrophages were infected with BCG at an MOI of 5:1 and
incubated at 37uC, 5% CO2. Infected cells at 4 hr post infection
were washed twice with RPMI without antibiotics to remove un-
ingested and un-adhered bacteria to minimize cell death and re-
incubated for a further 16 hours. The cells were washed once in
16distilled PBS before 350 mL RTL buffer was added to lyse the
cells and RNA extraction was then carried out using the RNeasy
Mini Kit (Qiagen, Germany), according to the manufacturer’s
instructions.
C57BL/6 Mice Infected with Acute TB
C57BL/6Jbrc female mice (18–19 weeks old) were purchased
from the Medical Research Centre (Biopolis, Singapore) from the
specific pathogen free (SPF) facility. Mice were kept at the Novartis
Institute for Tropical Diseases (NITD, Singapore) ABSL-3 facility
for a week before the experiment. The experiment was approved
by the Institute Animal Care and Use Committee of NITD. A
total of eleven mice were used. Five mice were infected
intravenously with 0.2 ml (approximately 106 CFU) of M.tb
Erdman strain. Six mice served as mock infected controls.
Briefly, M.tb Erdman strain was grown in Dubos broth to the
logarithmic stage. Bacteria were diluted in saline containing 0.05%
Tween 80 for infection in mice. Mock infected mice were
intravenously administered PBS containing 0.05% Tween 80.
After four weeks, infected and control mice were sacrificed. Half of
the lungs was immersed in saline containing 0.05% Tween 80 for
homogenizing to determine the CFU (data not shown) and the
other half was immersed in the RNA laterH stabilizer solution
(AmbionH, USA) prior to preparing tissue lysate for extracting
total RNA.
Figure 7. Ingenuity pathway analysis of the key genes identified. Ingenuity pathway analysis of the genes differentially regulated and
common to the three systems described above (in orange). Network of genes in the interferon 1 signaling pathways that were found to be common
in active TB patients, BCG-infected THP-1 cells at 20 hours and mice infected with active TB are illustrated. The lines in between genes represent
known interactions, with solid lines representing direct interactions and dashed lines representing indirect interactions.
doi:10.1371/journal.pone.0045839.g007
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RNA Extraction from Mice Lungs
For preparation of tissue lysate, lung tissue immersed in the
RNA laterH stabilizer solution (AmbionH, USA) was transferred to
the lysing Matrix D tube of FastPrep system Pro Green Kit (Plants
and Animals) (Qbiogen, Germany). Tissue lysate was then
prepared according to the manufacturer’s instructions.
Total RNA was extracted from tissue lysate using the RNA Easy
kit (Qiagen, Germany). Extracted RNA was subjected to DNAse
treatment using RNAse free DNAse Set (Qiagen, Germany).
Integrity of the RNA was assessed by 1% agarose gel electropho-
resis and samples of poor quality were excluded from analysis.
Microarrays
Total RNA (250 ng) was amplified in a single round of in vitro
transcription amplification that allowed incorporation of biotin-
labelled nucleotides using the Illumina TotalPrep RNA amplifi-
cation kit (Ambion, Austin, TX), according to the manufacturer’s
instructions. cRNA (750 ng) of each sample was hybridized to an
Illumina HumanRef-8 V3 BeadChip (containing probes to 24526
RefSeq gene sequences) at 58uC for 16 hours according to the
manufacturer’s instructions (Illumina, Inc., San Diego, CA). This
was followed by washing, blocking and streptavidin-Cy3 staining
steps, followed by scanning with a high resolution Illumina bead
array reader confocal scanner, according to the manufacturer’s
instructions. For all arrays at the different time points, a rigorous
quality check was carried out to ensure good performance before
the array data was extracted. The data extraction was performed
by using Illumina BeadStudio v3 software and uploaded into
Genespring GX10 (Silicon Genetics, Redwood City, CA) software
for downstream analysis.
Array Normalization
The standard normalization procedures recommended by
Genespring software for one-colour array were followed. Data
transformation was corrected for a low signal, with values recorded
at ,0.01 increased to the minimum (0.01). Chip variability was
accounted for using per-chip normalization by dividing all of the
measurements on each chip by a 75th percentile value. Probe set
variability for different genes were accounted for using per-gene
normalization by dividing all genes by the median of all genes.
Analysis was restricted to probe sets for which a detection level of
0.9899 was obtained in at least 50% of arrays in at least one
condition stated. Following quality control of probes, statistical
analysis, hierarchical clustering and functional classification were
performed.
Selection of Differentially Expressed Genes from
Microarray Data
Differentially expressed genes were selected from the normal-
ized data by using a procedure known as significance analysis of
microarrays (SAM) [39] as installed on Genespring GX10. The
statistic in SAM is given as d= (u12u2)/(s2s0), where the
numerator is the group mean difference, s is the standard error
and s0 is a regularizing constant. Setting s0 = 0 will yield a t-
statistic. This value, called the fudge constant, is found by
removing the trend in d as a function of s in moving windows
across the data to reduce false positive results. Since the statistic is
not t-distributed, significance is computed using a permutation
test. Genes with computed statistic larger than the threshold are
called significant. 1000 permutations were conducted and a
threshold false discovery rate (FDR) of 0.05 set to determine the
differentially expressed genes which were significant, and subse-
quently subjected to filtering through fold change of 2 or greater.
Clustering using Self Organizing Map (SOM) function was used
to group genes with different gene expression profiles, with
Euclidean distance metric, a maximum iterations of 50, grid rows
of 3 by 4, initial learning rate of 0.03, initial neighborhood radius
of 5, neighborhood bubble type, with a hexagonal grid topology.
Gene Ontology Clustering
The PANTHER (www.pantherdb.org) online gene expression
analysis system was used to group significantly overrepresented
genes into functional relationships. Similarly, the Ingenuity
Pathway Analysis (IPA; www.ingenuity.com) was also used to
classify differentially expressed genes into functional relationships
and further show canonical pathways and networks involving these
genes, with nodes defining potentially critical host mediators of
infection. The canonical pathways are described in the library of
the Ingenuity Pathways knowledge base and are based on well-
known established textbook literature where molecular links are
known. The networks are built from a compilation of literature
searches. Connecting lines between nodes represent one or more
publications which imply a direct or indirect connection between
the genes. The Ingenuity program is updated monthly to reflect
new publications.
For canonical pathways, the significance of the association was
measured in two ways: (i) by the ratio of the number of genes from
the data set that map to the pathway divided by the total number
of genes in that pathway and (ii) by using the Benjamin-Hochberg
multiple corrected p-value to obtain a p-value determining the
probability that the association between the genes in the data set
and the canonical pathway is explained by chance alone,
correcting for multiple testing of the same genes against different
canonical pathways.
Network-wise, IPA computes a score for each network related to
the fit of the input set of differentially expressed genes. The score is
obtained from the likelihood that the focus genes in a network are
together due to chance alone, with a score of 2 being equivalent to
a p-value of 0.01.
Quantitative RT-PCR (qRT-PCR) by Fluidigm System
Using the extracted RNA from the three systems above, 100 ng
of total RNA was reverse transcribed using the High-Capacity
cDNA Kit for 1000 reactions (ABI, USA), and processed for the
48.48 Fluidigm Microfluidic Chips, according to the manufactur-
er’s instructions, together with data analysis using the Biomark
qRT-PCR analysis and Biomark Melting Curve analysis software
(Fluidigm, USA). We normalized the qRT-PCR data in relation to
a reference gene expression quantitation using the gene 18S,
according to well established procedures. The RNA samples used
for PCR were the same as those used for the microarray.
Microarray Statistical Analysis
For microarray analysis, the Illumina HumanRef-8 V3
BeadChip was utilized, containing more than 24,000 genes. For
the initial analysis, the T-test with Benjamin-Hochberg procedure
was used to determine differentially expressed genes from the
normalized data in any one condition from the controls (see
Materials and Methods). Analysis of variance (ANOVA) was used
to determine differentially expressed genes across patient groups.
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